Categories: Opinion

India’s chance to supply hydroxychloroquine to world

As the world looks at India to ramp up exports of the antimalarial drug hydroxychloroquine (HCQ), now used to treat COVID-19 patients, it is time for the Narendra Modi government to seize this huge opportunity. India, which had banned the export of HCQ to ensure there was no shortage of the drug in the domestic market, has decided to allow its shipment outside the country after the US administration sought its supply.

Trump, who spoke of retaliation in case India decided not to export the drug, was quick to thank Modi saying that this act “will not be forgotten.”

Not the just the US, many other countries including Brazil too have sought supply of the drug from India, which manufactures 70 per cent of the world’s total requirement.

In fact, this has opened up a huge opportunity for India to make a mark in the global medicinal arena by increasing its exports to several countries hit by the deadly COVID 19.

While India had been exporting HCQ till recently, this is the time to seize the opportunity to enhance exports of other drugs and medical equipment as well. This is the time to strengthen and boost its Make in India scheme and displace China, a major supplier of active pharmaceutical ingredients (API) across the globe.

Companies such as Ipca Laboratories, Cadila Healthcare (Zydus Cadila), Torrent Pharmaceuticals, and Wallace Pharmaceuticals that produce this drug are working overtime to ensure that there is enough supply to ensure that there is no shortage in the domestic market while meeting the enhanced export orders.

India has the capacity to manufacture about 20 crore tablets of 200 mg each per month. This is the time to ramp up production of this tablet, which is not manufactured in the US or European countries.

A chunk of the API, used to manufacture HCQ, comes from China but supplies so far remained steady. But there is no reason why Indian companies cannot boost production of the API.

Zydus Cadila, Mangalam Drugs, and Vital Laboratories are already producing the raw materials for this drug. It is the need of the hour to look at this in a more holistic manner to ensure that the supply of raw material as well as the production of medicines is increased, not only for Indian markets but also the world.

The government, on its part, must ensure that a seamless supply chain.

Many pharmaceutical companies have been facing problems due to dearth of labor at this critical juncture and uncertainty arising on the transport front, both crucial to allow timely supply.

It could be a game changing moment for India. It must not let this opportunity go..

Mahua Venkatesh

Mahua Venkatesh specialises in covering economic trends related to India and the world along with developments in South Asia.

Recent Posts

New Zealand Foreign Minister arrives Kathmandu on two days’ visit, ahead Everest Day

New Zealand's Deputy Prime Minister and Foreign Minister Winston Peters has arrived Kathmandu on his…

10 hours ago

Indian, Mongolian armies to hold 17th ‘Nomadic Elephant 2025’ joint exercise in Ulaanbaatar

The Indian Army and the Mongolian Armed Forces will commence the 17th edition of their…

13 hours ago

“Never thought this would happen…”: Pandi Ram Mandavi on receiving Padma Shri for wood craft

Pandi Ram Mandavi, a renowned artist from Bastar, Chhattisgarh, was conferred the Padma Shri award…

13 hours ago

Taiwan slams China’s Cross-Strait summits as ‘United Front Lectures,’ shuns events in Beijing

Taiwan's Mainland Affairs Council (MAC) criticised China on Wednesday for organising two summits for Taiwanese…

15 hours ago

ETGE slams UNWTO official for endorsing China’s tourism drive amid ongoing Uyghur genocide

The East Turkistan Government in Exile (ETGE) vehemently denounces Mr. Francesco Frangialli, the Honorary Secretary-General…

15 hours ago

US lawmakers urge AI Safety Institute to counter China’s growing AI threat

Chairman John Moolenaar and Ranking Member Raja Krishnamoorthi of the House Select Committee on the…

16 hours ago